NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $245.43 +1.89 (+0.78%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$245.53 +0.10 (+0.04%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$240.77▼$246.4750-Day Range$205.06▼$247.5752-Week Range$132.10▼$266.38Volume576,689 shsAverage Volume854,833 shsMarket Capitalization$15.75 billionP/E Ratio83.48Dividend YieldN/APrice Target$293.00Consensus RatingModerate Buy Company Overview Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation. Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines. Bruce Cozadd, a company co-founder, serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreJAZZ MarketRank™: 4.78625148436 of 5 starsJazz Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 8th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialJazz Pharmaceuticals has a consensus price target of $293.00, representing about 19.4% upside from its current price of $245.43.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth112.09% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 112.09% in the coming year, from $11.08 to $23.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 21.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 21.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.01.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.44. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.42% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.67.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 1.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentJazz Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Jazz Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest20 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 186% compared to the previous 30 days.MarketBeat Follows3 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,420,491.00 in company stock.Percentage Held by Insiders4.10% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JAZZ Stock News HeadlinesJazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 68,808 Shares of Company Stock12 minutes ago | insidertrades.comJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Consensus Target Price of $293.45 According to AnalystsNovember 9 at 2:44 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $326,911.68 in StockNovember 7, 2026 | insidertrades.comJazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded by Wall Street Zen to "Hold"November 7, 2026 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells 1,000 Shares of Company StockNovember 6, 2026 | insidertrades.comJazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,295,040.00 in StockNovember 5, 2026 | insidertrades.comJazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysNovember 5, 2026 | americanbankingnews.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $170.00 at the beginning of the year. Since then, JAZZ shares have increased by 44.4% and is now trading at $245.43. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings data on Monday, November, 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The company's revenue was up 10.4% compared to the same quarter last year. Read the conference call transcript. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' top institutional investors include William Blair Investment Management LLC (0.67%), Boston Trust Walden Corp (0.65%), Argent Capital Management LLC (0.30%) and Retirement Systems of Alabama (0.26%). Insiders that own company stock include Bruce C Cozadd, Renee D Gala, Seamus Mulligan, Robert Iannone, Neena M Patil, Mary Elizabeth Henderson, Philip L Johnson, Heather Ann Mcsharry, Mark Douglas Smith, Rick E Winningham, Norbert G Riedel and Patricia Carr. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA) and Alphabet (GOOG). Company Calendar Last Earnings11/02/2026Today11/10/2026Jefferies Global Healthcare Conference11/17/202638th Annual Healthcare Conference12/02/2026Citi Annual Global Healthcare Conference 202612/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, JAZZ's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,890Year Founded2003Price Target and Rating Average Price Target for Jazz Pharmaceuticals$293.00 High Price Target$337.00 Low Price Target$220.00 Potential Upside/Downside+19.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)$2.94 Trailing P/E Ratio83.48 Forward P/E Ratio10.44 P/E Growth0.44Net Income-$356.15 million Net Margins4.37% Pretax Margin5.51% Return on Equity16.88% Return on Assets6.46% Debt Debt-to-Equity Ratio1.09 Current Ratio1.82 Quick Ratio1.64 Sales & Book Value Annual Sales$4.27 billion Price / Sales3.69 Cash Flow$16.38 per share Price / Cash Flow14.98 Book Value$65.30 per share Price / Book3.76Miscellaneous Outstanding Shares64,190,000Free Float61,557,000Market Cap$15.75 billion OptionableOptionable Beta0.38 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:JAZZ) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is Available to ClaimJames Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
